The influance of mildronate on non-specific resistance in diabetic patients (second report)

It has been shown that in the complex therapy of diabetic patients the use of mildronate leads to a marked increase of non-specific resistance to the content of non-ensymic cation proteins in neutrophilocytes of blood compared wiht the studied data in patients in whom the mentioned above drug was not given during the treatment. Having analyzed results both of the given work and our own multiple experiments carried out to study biological activity of mildronate we can recommend to take this drug for complex treatment of diabetic patients in any stages of the disease to correct non-specific resistance of the body.